

Aging is not programmed

Genetic pseudo-program is a shadow of developmental growth

Mikhail V Blagosklonny

Cell Stress Biology; Roswell Park Cancer Institute; Buffalo, NY USA

Keywords: senescence, geroconversion, gerosuppression, rapamycin, rapalogs, evolution, selection

Aging is not and cannot be programmed. Instead, aging is a continuation of developmental growth, driven by genetic pathways such as mTOR. Ironically, this is often misunderstood as a sort of programmed aging. In contrast, aging is a purposeless quasi-program or, figuratively, a shadow of actual programs.

“The brightest flame casts the darkest shadow.”
-George Martin

Introduction

Genes regulate lifespan, in some cases, dramatically.¹⁻¹⁷ Pro-aging genes encode signaling pathways such as the insulin/PI3K/TOR pathway that accelerate aging.¹³⁻¹⁶ These signal-transduction pathways are essential for development, growth, and survival early in life.¹⁸ Furthermore, the same signaling pathways drive cellular geroconversion: a conversion from cellular quiescence to senescence.¹⁹⁻⁴⁰ The same PI3K/TOR pathway is also involved in cancer and other age-related diseases.⁴¹⁻⁴⁴ The mTOR pathway links development and aging,⁴² cellular growth and senescence,⁴³ robustness early in life and diseases later in life,^{44,45} puberty and menopause.⁴⁶⁻⁴⁸ Whereas development and growth are programmed, aging and diseases are not. They are aimless continuations of the program that was not switched off upon its completion. Somehow these notions are confused with programmed aging theory. As discussed,^{41,49-52} it is only development that is programmed for purpose, aging is not. It is a shadow. Natural selection cannot eliminate the shadow. Nature simply selects for the brightest flame, which in turn casts the darkest shadow.

What Are Programmed Theories of Aging

Aging and its diseases are so orderly that the explanation begs for a program. Like development, aging seems to be programmed.⁵³⁻⁵⁷ Programmed theories are thought-provocative and

inspiring. They brilliantly illuminate limitations of mainstream theories that aging is a stochastic, random process.^{53,58} Also, while stochastic aging cannot be prevented,⁵⁹ the program can be switched off.⁶⁰⁻⁶³ This makes programmed theories appealing. But why would nature program aging? It was suggested that aging is beneficial for species and groups.⁵³ There are conditions for group selection in humans, given that human groups had the means to exterminate each other, or using modern terms, to commit genocide. But even group selection cannot select for aging and age-related diseases. In contrast, it should select for robust soldiers, who defend the group from extermination (in human societies and social ants). It was also suggested that organisms undergo programmed death, similar to apoptosis in the multicellular organism.⁶⁴ Still, aging (at least in humans) is a decades-long process of developing age-related diseases (cancer, hypertension, diabetes, blindness) that terminate life. This is an inefficient way to commit suicide. According to programmed theories, aging prevents overpopulation, speeds up evolution, or benefits young animals, by eliminating old (“less valuable”) animals. But old animals seem less “valuable” precisely because of aging. Thus, aging is programmed to eliminate less valuable animals because of aging. This is a circular reasoning. The only way out from this circle is to suggest that the aging process exists independently of a putative “suicidal program”. But if so, then such a putative program is irrelevant to aging.

Is Aging Programmed in Yeast?

Yeast death in stationary cultures, also known as chronologic senescence, may seem to be programmed.^{53,65-67} Yeast secretes toxic substances (pheromones, acetic acid, etc.). If “altruistic” yeast die, then other yeast may survive. However, so-called “altruistic” yeast may be less resistant to pH and toxic substances. This simply may be a classic case of survival of the fittest (resistant) yeast. Yeast chronological aging is similar to metabolic self-destruction of human cancer cells.⁶⁸ In stationary culture, cancer cells acidify the medium with lactic acid. When most cancer cells die, a few cells may survive. Are cancer cells altruistic? In yeast and cancer cell stationary cultures, acid-resistant cells survive. The main difference is that yeast produce acetic acid, whereas cancer cells produce lactic acid.⁶⁸⁻⁷² In yeast, “oncogenic” pathways such as Ras and TOR accelerate chronological senescence.⁷³⁻⁷⁵ Inhibitors of the TOR pathway, including rapamycin, decelerate chronological

Correspondence to: Mikhail V Blagosklonny; Email: Mikhail.blagosklonny@roswellpark.org, blagosklonny@oncotarget.com
Submitted: 11/11/2013; Accepted: 11/13/2013
<http://dx.doi.org/10.4161/cc.27188>

senescence in yeast.⁷⁵⁻⁷⁷ Rapamycin decelerates “yeast-like chronological senescence” in overcrowded cancer cell culture.⁶⁸ The same signaling pathways (such as TOR) that are involved in chronological senescence in yeast are also involved in metabolic self-destruction of cancer cells.^{68,73,74,78-81} The same pathways are also involved in cellular geroconversion, organismal aging, and age-related diseases (see ref. 68).

Programmed Elements in Non-Programmed (Stochastic) Theories

Programmed theories neither specify nor predict mechanisms of death. Ironically, it was suggested that programmed aging is caused by free radicals.⁵³ And, vice versa, mainstream (stochastic, decay) theories accept special programs (Table 1). For example, it was suggested that menopause in women is purposefully programmed to stop reproduction and to raise grandchildren instead.⁸² Also, it was suggested that the rate of aging is regulated by allocation of energetic resources:⁸³ paradoxically, the more available, the less used.⁸³ It is also thought that aging is programmed in Pacific salmon,⁸⁴ yet, salmon die from pathologies similar to mammalian age-related diseases. Neither aging and nor age-related diseases in Pacific salmon (or any other animals) are programmed. Aging in Pacific salmon and menopause in women are quasi-programmed.^{46,85}

Quasi-Programmed Hyperfunction (Aging)

Quasi-programmed aging is not something between “random damage” and “programmed” aging. Instead, quasi-programmed theory is absolutely different from both random damage and programmed theories (Table 1). According to quasi-programmed theory,^{41,42,44,45,49,50,52,86-90} neither aging nor menopause is programmed, they are manifestations of the aging process, which, in turn, is a pseudo-program of developmental growth. There is a

mechanistic link between mTOR-driven geroconversion, aging, and age-related pathologies, explaining how cellular hyperfunctions eventually lead to organismal death.⁴¹

Quasi-programmed theory predicts mechanisms of aging that are determined by mechanisms of growth, differentiation, and development. There is no need to guess what might be the mechanisms. Aging is a shadow. Its shape is determined by the developmental growth. This can be modeled in cell culture, revealing how growth can be converted to aging.

Quasi-Program of Cellular Senescence

Nutrients, growth factors, hormones, and cytokines all activate nutrient-sensing and growth-promoting signaling pathways such as mTOR (target of rapamycin). mTOR stimulates growth and anabolic metabolism, inhibits autophagy, and increases cellular functions.⁹¹⁻¹⁰² Cells grow in size, progress through the cell cycle, and then divide. In the absence of growth factors, normal cells become quiescent: they neither grow nor cycle. In When the cell is stimulated to grow, while the cell cycle is arrested, then the cell becomes senescent (geroconversion).⁴³ mTOR drives growth (program) and geroconversion (quasi-program) (Fig. 1). Also, cellular senescence can be viewed as a continuation of differentiation. The same cytokines that initially cause growth and proliferation then cause cell cycle arrest and differentiation.¹⁰³⁻¹⁰⁶ During differentiation, cells acquire and amplify specific functions. One example of cellular function is secretion of cytokines, hormones, matrix, enzymes, metabolites, or lipoproteins, depending on cell type. Other examples include contraction of smooth muscle cells, adhesion, and aggregation of platelets as well as oxidative burst of neutrophils.

The same intracellular signaling pathways that initially drive proliferation, and then differentiation, also stimulate functions in differentiating cells. Cell senescence-associated hypertrophy and hyper-functions are a continuation of growth (Fig. 1).

Table 1. Comparison of 3 groups of theories of aging: programmed, stochastic, and quasi-programmed

Theories	Defining feature	Purposeful?	Programmed?	Caused by ROS?	Kills via age-related diseases?	Causes death directly?	Menopause in women is	Link between aging and diseases	Use of energetic resources
Programmed	functional decline	yes	yes	mostly	unspecified	yes	programmed	unspecified	unspecified
Stochastic	functional decline	sometimes*	in some cases*	mostly	sometimes#	yes	programmed	vulnerability to diseases#	slows aging (via repair)
Quasi-programmed	hyperfunction	no	no	no	always	no	prototypical disease	manifested by diseases	fuels aging (via TOR)

According to stochastic theories, aging is caused by random accumulation of damages, errors, and “garbage” due to multiple causes including but not limited to free radicals. *Stochastic theories still accept that aging can be purposefully programmed (e.g., in salmon). #According to stochastic theories, aging can kill directly (by non-specified mechanisms) and also increases the vulnerability to age-related diseases.

From Cellular to Organismal Aging

The most relevant hallmark of cellular aging is hypertrophy/hyperfunctions and compensatory signal resistance, such as insulin resistance. Hyper-functions coupled with signal resistance cause loss of homeostasis, malfunction, organ damage, and death. The link between hyper-functions, including hypertrophy, and diseases has been discussed^{41,42,50,78,107-110} and will be discussed further (“Aging: From fiction to hyperfunction”, in press).

Quasi-Program of Aging

Genetic programs determine developmental growth and the onset of reproduction. When these programs are completed, they are not switched off.

Thus, programs become quasi-programs (Fig. 2). Specific characteristics of quasi-programs of aging and age-related diseases were discussed in detail.^{41-45,49-52,86-90} The evolutionary theory predicts quasi-programs, like it predicts genes harmful later in life, if they are useful earlier in life.⁴⁹ I emphasize that the quasi-program does not exist for its own sake: it is a shadow. Aging has no purpose (neither for individuals nor for group), no intention. Nature does not select for quasi-programs. It selects for robust developmental growth. Accelerated aging is the price for robustness.^{46,50,52,88,111} Although (in some conditions) natural selection works against quasi-programs of aging, it cannot eliminate them without harming development. Genes that drive aging are needed in development. Knockout of PI3K extends the lifespan of *C. elegans* 10-fold.¹² But this comes at a price: prolonged development. Even further, disruption of the mTOR gene leads to post-implantation lethality in mice.¹¹²⁻¹¹⁵ Whereas disruption of S6K1 extends lifespan in mice,¹⁴ knockout of both S6K1 and S6K2 causes perinatal lethality.¹¹⁶ In *Drosophila*, TOR is required for normal growth during larval development.¹¹⁷

The Utility of the Model

Mechanisms of aging are not arbitrary but determined by mechanisms of development and growth. Since development and growth are relatively well understood, we can interpolate this knowledge to studying aging. For example, it is known that mTOR drives cellular mass growth. This predicts that p53 and hypoxia, which inhibit mTOR and cellular mass growth, will suppress geroconversion despite causing cell cycle arrest.^{25,26,118-120} Thus, like other tumor suppressors,⁴³ p53 and hypoxia may play a dual role in aging.¹²¹⁻¹²⁸ The map of growth-promoting signaling network can be interpolated to aging. Gerogenes (insulin receptor, PI-3K, Akt, mTOR) and gerosuppressors (PTEN, TSC, AMPK) form a network, which (in analogy with the periodic “Mendeleev” table) predicts the effect of a particular gene on aging and diseases.¹²⁹ Basically, genes that activate the mTOR pathway are gerogenes, and those that antagonize the pathway are gerosuppressors.^{43,129} As another example, developmental trends, such as an increase in blood pressure, near vision point, and FSH levels (all necessary for development and reproductive functions) cause hypertension, presbyopia, and menopause, respectively,




Figure 1. From cellular growth to hypertrophic senescence (geroconversion). Geroconversion (geroconversion) from cellular growth to cellular aging, when the cell cycle is arrested. Geroconversion is a continuation of growth driven by mTOR and related pathways.




Figure 2. From developmental growth (program) to aging (shadow). Quasi-programmed aging is driven by over-activation of signal-transduction pathways such as TOR and exacerbation of normal cellular functions, which become harmful (hyper-function), leading to alterations of homeostasis, malfunctions, diseases, and organ damage.

later in life.⁸⁹ Many predictions of the quasi-programmed aging model⁴² were confirmed by 2010,⁸⁷ including the prediction that rapamycin will extend lifespan in mice.¹³⁰ Numerous recent publications further illuminate the role of the mTOR pathway (and related pathways) in aging.^{35,131-168}

If used properly, rapamycin improves immunity and decreases infections and their complications.^{148,169,170} Under certain conditions, rapamycin can exert immunostimulatory effects, boosting T-cell responses in the face of pathogen infections and vaccines.^{170,171} Rapamycin may improve response against pathogens but prevent transplant rejection.^{172,173}

Conclusion

The essence of quasi-program was discussed previously.^{42,89} Here I addressed a misunderstanding that a quasi-program is a sort of a program. It is not (Table 1). Whereas the growth of the body is programmed, the emergence of the shadow is not. Natural selection cannot eliminate the shadow without hurting the “body”. As a case in point, mTOR knockout is lethal in embryogenesis. However, pharmacologic interventions can be started in post-development, thus extending healthy lifespan. mTOR-driven quasi-program can be suppressed pharmacologically.¹⁷⁴ And this is what is actually important. After all, according to Oscar Wilde, “*What men call the shadow of the body is not the shadow of the body, but is the body of the soul.*”

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A *C. elegans* mutant that lives twice as long as wild type. *Nature* 1993; 366:461-4; PMID:8247153; <http://dx.doi.org/10.1038/366461a0>
2. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. *Nature* 2000; 408:255-62; PMID:11089983; <http://dx.doi.org/10.1038/35041700>
3. Partridge L, Gems D. Mechanisms of ageing: public or private? *Nat Rev Genet* 2002; 3:165-75; PMID:11972154; <http://dx.doi.org/10.1038/nrg753>
4. Hekimi S, Guarente L. Genetics and the specificity of the aging process. *Science* 2003; 299:1351-4; PMID:12610295; <http://dx.doi.org/10.1126/science.1082358>
5. Sinclair DA, Guarente L. Unlocking the secrets of longevity genes. *Sci Am* 2006; 294:48-51, 54-7; PMID:16502611; <http://dx.doi.org/10.1038/scientificamerican0306-48>
6. Gardner MP, Gems D, Viney ME. Extraordinary plasticity in aging in *Strongyloides ratti* implies a gene-regulatory mechanism of lifespan evolution. *Aging Cell* 2006; 5:315-23; PMID:16913877; <http://dx.doi.org/10.1111/j.1474-9726.2006.00226.x>
7. Kenyon CJ. The genetics of ageing. *Nature* 2010; 464:504-12; PMID:20336132; <http://dx.doi.org/10.1038/nature08980>
8. Kaeberlein M. Longevity and aging. *F1000Prime Rep* 2013; 5:5; PMID:23513177; <http://dx.doi.org/10.12703/P5-5>
9. Gladyshev VN, Zhang G, Wang J. The naked mole rat genome: understanding aging through genome analysis. *Aging (Albany NY)* 2011; 3:1124; PMID:22199030
10. Bartke A, Coschigano K, Kopchick J, Chandrasekar V, Mattison J, Kinney B, Hauck S. Genes that prolong life: relationships of growth hormone and growth to aging and lifespan. *J Gerontol A Biol Sci Med Sci* 2001; 56:B340-9; PMID:11487592; <http://dx.doi.org/10.1093/gerona/56.8.B340>
11. Bartke A. Insulin and aging. *Cell Cycle* 2008; 7:3338-43; PMID:18948730; <http://dx.doi.org/10.4161/cc.7.21.7012>
12. Ayyavevara S, Alla R, Thaden JJ, Shmookler Reis RJ. Remarkable longevity and stress resistance of nematode PI3K-null mutants. *Aging Cell* 2008; 7:13-22; PMID:17996009; <http://dx.doi.org/10.1111/j.1474-9726.2007.00348.x>
13. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in *Drosophila* by modulation of genes in the TOR signaling pathway. *Curr Biol* 2004; 14:885-90; PMID:15186745; <http://dx.doi.org/10.1016/j.cub.2004.03.059>
14. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadan F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian lifespan. *Science* 2009; 326:140-4; PMID:19797661; <http://dx.doi.org/10.1126/science.1177221>
15. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. *Nature* 2013; 493:338-45; PMID:23325216; <http://dx.doi.org/10.1038/nature11861>
16. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. *Cell Rep* 2013; 4:913-20; PMID:23994476; <http://dx.doi.org/10.1016/j.celrep.2013.07.030>
17. Hoffmann J, Romey R, Fink C, Yong L, Roeder T. Overexpression of Sir2 in the adult fat body is sufficient to extend lifespan of male and female *Drosophila*. *Aging (Albany NY)* 2013; 5:315-27; PMID:23765091
18. Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. *Aging (Albany NY)* 2009; 1:357-62; PMID:20157523
19. Blagosklonny MV. Cell senescence and hypermitogenic arrest. *EMBO Rep* 2003; 4:358-62; PMID:12671679; <http://dx.doi.org/10.1038/sj.embor.embor806>
20. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. *Cell Cycle* 2008; 7:3355-61; PMID:18948731; <http://dx.doi.org/10.4161/cc.7.21.6919>
21. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. *Cell Cycle* 2009; 8:1888-95; PMID:19471117; <http://dx.doi.org/10.4161/cc.8.12.8606>
22. Demidenko ZN, Shuttman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. *Cell Cycle* 2009; 8:1896-900; PMID:19478560; <http://dx.doi.org/10.4161/cc.8.12.8809>
23. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. *Aging (Albany NY)* 2009; 1:1008-16; PMID:20157583
24. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. *Aging (Albany NY)* 2010; 2:344-52; PMID:20606252
25. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. *Proc Natl Acad Sci U S A* 2010; 107:9660-4; PMID:20457898; <http://dx.doi.org/10.1073/pnas.1002298107>
26. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. *Proc Natl Acad Sci U S A* 2012; 109:13314-8; PMID:22847439; <http://dx.doi.org/10.1073/pnas.1205690109>
27. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. *Cell Cycle* 2009; 8:4112-8; PMID:19946210; <http://dx.doi.org/10.4161/cc.8.24.10215>
28. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. *Aging (Albany NY)* 2010; 2:924-35; PMID:21212465
29. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyper-elevation during geroconversion. *Cell Death Differ* 2013; 20:1241-9; PMID:23852369; <http://dx.doi.org/10.1038/cdd.2013.86>
30. Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and mTOR activity determine geroconversion. *Cell Cycle* 2013; 12:3063-9; PMID:23974099; <http://dx.doi.org/10.4161/cc.26130>
31. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. *Cell Cycle* 2012; 11:2391-401; PMID:22627671; <http://dx.doi.org/10.4161/cc.20683>
32. Darzynkiewicz Z. Forever young, slim and fit: rapamycin to the rescue. *Cell Cycle* 2009; 8:1820-1; PMID:19471126; <http://dx.doi.org/10.4161/cc.8.12.8967>
33. Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, Fornace AJ Jr., Pospelova TV, Pospelov VA. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. *Cell Cycle* 2010; 9:3945-55; PMID:20935470; <http://dx.doi.org/10.4161/cc.9.19.13160>
34. Zhao H, Halicka HD, Li J, Darzynkiewicz Z. Berberine suppresses gero-conversion from cell cycle arrest to senescence. *Aging (Albany NY)* 2013; 5:623-36; PMID:23974852
35. Halicka HD, Zhao H, Li J, Lee YS, Hsieh TC, Wu JM, Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. *Aging (Albany NY)* 2012; 4:952-65; PMID:23363784
36. Chen C, Liu Y, Liu Y, Zheng P. The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells. *Cell Cycle* 2009; 8:1158-60; PMID:19270502; <http://dx.doi.org/10.4161/cc.8.8.8139>
37. Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. *Cell Cycle* 2009; 8:1003-6; PMID:19270523; <http://dx.doi.org/10.4161/cc.8.7.8045>
38. Narita M, Young AR, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, Hong S, Berry LS, Reichelt S, Ferreira M, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. *Science* 2011; 332:966-70; PMID:21512002; <http://dx.doi.org/10.1126/science.1205407>
39. Young AR, Narita M, Narita M. Spatio-temporal association between mTOR and autophagy during cellular senescence. *Autophagy* 2011; 7:1387-8; PMID:21799306; <http://dx.doi.org/10.4161/auto.7.11.17348>
40. Fujii S, Hara H, Araya J, Takasaka N, Kojima J, Ito S, Minagawa S, Yumino Y, Ishikawa T, Numata T, et al. Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease. *Oncoimmunology* 2012; 1:630-41; PMID:22934255; <http://dx.doi.org/10.4161/onci.20297>
41. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". *Aging (Albany NY)* 2012; 4:861-77; PMID:23425777
42. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. *Cell Cycle* 2006; 5:2087-102; PMID:17012837; <http://dx.doi.org/10.4161/cc.5.18.3288>
43. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. *Aging (Albany NY)* 2012; 4:159-65; PMID:22394614
44. Blagosklonny MV. TOR-driven aging: speeding car without brakes. *Cell Cycle* 2009; 8:4055-9; PMID:19923900; <http://dx.doi.org/10.4161/cc.8.24.10310>
45. Blagosklonny MV. Big mice die young but large animals live longer. *Aging (Albany NY)* 2013; 5:227-33; PMID:23603822

46. Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. *Aging* (Albany NY) 2010; 2:265-73; PMID:20519781
47. Adhikari D, Liu K. mTOR signaling in the control of activation of primordial follicles. *Cell Cycle* 2010; 9:1673-4; PMID:20404510; <http://dx.doi.org/10.4161/cc.9.9.11626>
48. Luo LL, Xu JJ, Fu YC. Rapamycin prolongs female reproductive lifespan. *Cell Cycle* 2013; 12:3353-4; PMID:24091532; <http://dx.doi.org/10.4161/cc.26578>
49. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. *Cell Cycle* 2010; 9:3151-6; PMID:20724817; <http://dx.doi.org/10.4161/cc.9.16.13120>
50. Blagosklonny MV. Why the disposable soma theory cannot explain why women live longer and why we age. *Aging* (Albany NY) 2010; 2:884-7; PMID:21191147
51. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. *Aging* (Albany NY) 2011; 3:1051-62; PMID:22166724
52. Blagosklonny MV. MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. *Cell Cycle* 2013; 12:1842-7; PMID:23708516; <http://dx.doi.org/10.4161/cc.25062>
53. Longo VD, Mitteldorf J, Skulachev VP. Programmed and altruistic ageing. *Nat Rev Genet* 2005; 6:866-72; PMID:16304601; <http://dx.doi.org/10.1038/nrg1706>
54. Bredesen DE. The non-existent aging program: how does it work? *Aging Cell* 2004; 3:255-9; PMID:15379848; <http://dx.doi.org/10.1111/j.1474-9728.2004.00121.x>
55. Prinzinger R. Programmed ageing: the theory of maximal metabolic scope. How does the biological clock tick? *EMBO Rep* 2005; 6:S14-9; PMID:15995655; <http://dx.doi.org/10.1038/sj.embor.7400425>
56. de Magalhães JP. Programmatic features of aging originating in development: aging mechanisms beyond molecular damage? *FASEB J* 2012; 26:4821-6; PMID:22964300; <http://dx.doi.org/10.1096/fj.12-210872>
57. de Magalhães JP, Church GM. Cells discover fire: employing reactive oxygen species in development and consequences for aging. *Exp Gerontol* 2006; 41:1-10; PMID:16226003; <http://dx.doi.org/10.1016/j.exger.2005.09.002>
58. Mitteldorf J. Can experiments on caloric restriction be reconciled with the disposable soma theory for the evolution of senescence? [discussion 1906]. *Evolution* 2001; 55:1902-5, discussion 1906; PMID:11681746
59. Hayflick L. "Anti-aging" is an oxymoron. *J Gerontol A Biol Sci Med Sci* 2004; 59:B573-8; PMID:15215267; <http://dx.doi.org/10.1093/gerona/59.6.B573>
60. Skulachev VP, Longo VD. Aging as a mitochondria-mediated atavistic program: can aging be switched off? *Ann N Y Acad Sci* 2005; 1057:145-64; PMID:16399892; <http://dx.doi.org/10.1196/annals.1356.009>
61. Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Elichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, et al. An attempt to prevent senescence: a mitochondrial approach. *Biochim Biophys Acta* 2009; 1787:437-61; PMID:19159610; <http://dx.doi.org/10.1016/j.bbabi.2008.12.008>
62. Skulachev VP. SkQ1 treatment and food restriction--two ways to retard an aging program of organisms. *Aging* (Albany NY) 2011; 3:1045-50; PMID:22170754
63. Skulachev VP. Aging as a particular case of phenoptosis, the programmed death of an organism (a response to Kirkwood and Melov "On the programmed/non-programmed nature of ageing within the life history"). *Aging* (Albany NY) 2011; 3:1120-3; PMID:22146104
64. Skulachev VP. Programmed death phenomena: from organelle to organism. *Ann N Y Acad Sci* 2002; 959:214-37; PMID:11976198; <http://dx.doi.org/10.1111/j.1749-6632.2002.tb02095.x>
65. Herker E, Jungwirth H, Lehmann KA, Maldener C, Fröhlich KU, Wissing S, Büttner S, Fehr M, Sigrist S, Madeo F. Chronological aging leads to apoptosis in yeast. *J Cell Biol* 2004; 164:501-7; PMID:14970189; <http://dx.doi.org/10.1083/jcb.200310014>
66. Fabrizio P, Battistella L, Vardavas R, Gattazzo C, Liou LL, Diaspro A, Dossen JW, Gralla EB, Longo VD. Superoxide is a mediator of an altruistic aging program in *Saccharomyces cerevisiae*. *J Cell Biol* 2004; 166:1055-67; PMID:15452146; <http://dx.doi.org/10.1083/jcb.200404002>
67. Fabrizio P, Longo VD. Chronological aging-induced apoptosis in yeast. *Biochim Biophys Acta* 2008; 1783:1280-5; PMID:18445486; <http://dx.doi.org/10.1016/j.bbamer.2008.03.017>
68. Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. *Aging* (Albany NY) 2011; 3:1078-91; PMID:22156391
69. Burtner CR, Murakami CJ, Kennedy BK, Kaerberlein M. A molecular mechanism of chronological aging in yeast. *Cell Cycle* 2009; 8:1256-70; PMID:19305133; <http://dx.doi.org/10.4161/cc.8.8.8287>
70. Burtner CR, Murakami CJ, Kaerberlein M. A genomic approach to yeast chronological aging. *Methods Mol Biol* 2009; 548:101-14; PMID:19521821; http://dx.doi.org/10.1007/978-1-59745-540-4_6
71. Kaerberlein M. Lessons on longevity from budding yeast. *Nature* 2010; 464:513-9; PMID:20336133; <http://dx.doi.org/10.1038/nature08981>
72. Fabrizio P, Wei M. Conserved role of medium acidification in chronological senescence of yeast and mammalian cells. *Aging* (Albany NY) 2011; 3:1127-9; PMID:22184281
73. Longo VD. Ras: the other pro-aging pathway. *Sci Aging Knowledge Environ* 2004; 2004:pe36; PMID:15456908; <http://dx.doi.org/10.1126/sageke.2004.39.pe36>
74. Bonawit ND, Chatenay-Lapointe M, Pan Y, Shadel GS. Reduced TOR signaling extends chronological lifespan via increased respiration and upregulation of mitochondrial gene expression. *Cell Metab* 2007; 5:265-77; PMID:17403371; <http://dx.doi.org/10.1016/j.cmet.2007.02.009>
75. Powers RW 3rd, Kaerberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological lifespan in yeast by decreased TOR pathway signaling. *Genes Dev* 2006; 20:174-84; PMID:16418483; <http://dx.doi.org/10.1101/gad.1381406>
76. Alvers AL, Wood MS, Hu D, Kaywell AC, Dunn WA Jr., Aris JP. Autophagy is required for extension of yeast chronological lifespan by rapamycin. *Autophagy* 2009; 5:847-9; PMID:19458476
77. Pan Y, Shadel GS. Extension of chronological lifespan by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. *Aging* (Albany NY) 2009; 1:131-45; PMID:20157595
78. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. *Aging* (Albany NY) 2011; 3:1130-41; PMID:22246147
79. Kaerberlein M, Hu D, Kerr EO, Tsuchiya M, Westman EA, Dang N, Fields S, Kennedy BK. Increased lifespan due to caloric restriction in respiratory-deficient yeast. *PLoS Genet* 2005; 1:e69; PMID:16311627; <http://dx.doi.org/10.1371/journal.pgen.0010069>
80. Powers T. TOR signaling and S6 kinase 1: Yeast catches up. *Cell Metab* 2007; 6:1-2; PMID:17618850; <http://dx.doi.org/10.1016/j.cmet.2007.06.009>
81. Kennedy BK, Steffen KK, Kaerberlein M. Ruminations on dietary restriction and aging. *Cell Mol Life Sci* 2007; 64:1323-8; PMID:17396225; <http://dx.doi.org/10.1007/s00018-007-6470-y>
82. Shanley DP, Kirkwood TB. Evolution of the human menopause. *Bioessays* 2001; 23:282-7; PMID:11223885; [http://dx.doi.org/10.1002/1521-1878\(200103\)23:3<282::AID-BIES1038>3.0.CO;2-9](http://dx.doi.org/10.1002/1521-1878(200103)23:3<282::AID-BIES1038>3.0.CO;2-9)
83. Kirkwood TB, Austad SN. Why do we age? *Nature* 2000; 408:233-8; PMID:11089980; <http://dx.doi.org/10.1038/35041682>
84. Austad SN. Is aging programmed? *Aging Cell* 2004; 3:249-51; PMID:15379846; <http://dx.doi.org/10.1111/j.1474-9728.2004.00112.x>
85. Blagosklonny MV. Paradoxes of aging. *Cell Cycle* 2007; 6:2997-3003; PMID:18156807; <http://dx.doi.org/10.4161/cc.6.24.5124>
86. Blagosklonny MV. Program-like aging and mitochondria: instead of random damage by free radicals. *J Cell Biochem* 2007; 102:1389-99; PMID:17975792; <http://dx.doi.org/10.1002/jcb.21602>
87. Blagosklonny MV. Rapamycin and quasi-programmed aging: four years later. *Cell Cycle* 2010; 9:1859-62; PMID:20436272; <http://dx.doi.org/10.4161/cc.9.10.11872>
88. Blagosklonny MV. Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis. *Aging* (Albany NY) 2010; 2:177-82; PMID:20404395
89. Blagosklonny MV. Rapamycin extends life- and health span because it slows aging. *Aging* (Albany NY) 2013; 5:592-8; PMID:23934728
90. Blagosklonny MV. M(o)TOR of aging: MTOR as a universal molecular hypothalamus. *Aging* (Albany NY) 2013; 5:490-4; PMID:23872658
91. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006; 124:471-84; PMID:16469695; <http://dx.doi.org/10.1016/j.cell.2006.01.016>
92. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? *Aging* (Albany NY) 2009; 1:586-97; PMID:20157541
93. Yan L, Mיעulet V, Lamb RF. Nutrient regulation of mTORC1 and cell growth. *Cell Cycle* 2010; 9:2473-4; PMID:20543582; <http://dx.doi.org/10.4161/cc.9.13.12124>
94. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. *Mol Cell* 2010; 40:310-22; PMID:20965424; <http://dx.doi.org/10.1016/j.molcel.2010.09.026>
95. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. *Curr Opin Genet Dev* 2013; 23:53-62; PMID:23317514; <http://dx.doi.org/10.1016/j.gde.2012.12.005>
96. Bhaskar PT, Hay N. The two TORCs and Akt. *Dev Cell* 2007; 12:487-502; PMID:17419990; <http://dx.doi.org/10.1016/j.devcel.2007.03.020>
97. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. *Genetics* 2011; 189:1177-201; PMID:22174183; <http://dx.doi.org/10.1534/genetics.111.133363>

98. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 2011; 12:21-35; PMID:21157483; <http://dx.doi.org/10.1038/nrm3025>
99. Kim E, Guan KL. RAG GTPases in nutrient-mediated TOR signaling pathway. *Cell Cycle* 2009; 8:1014-8; PMID:19270521; <http://dx.doi.org/10.4161/cc.8.7.8124>
100. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell* 2013; 153:1194-217; PMID:23746838; <http://dx.doi.org/10.1016/j.cell.2013.05.039>
101. Hildebrand DG, Lehle S, Borst A, Haferkamp S, Essmann F, Schulze-Osthoff K. α -Fucosidase as a novel convenient biomarker for cellular senescence. *Cell Cycle* 2013; 12:1922-7; PMID:23673343; <http://dx.doi.org/10.4161/cc.24944>
102. Völkers M, Sussman M. mTOR/PRAS40 interaction: Hypertrophy or proliferation. *Cell Cycle* 2013; 12: In press; PMID:24131922; <http://dx.doi.org/10.4161/cc.26822>
103. Ogawa M. Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation. *Environ Health Perspect* 1989; 80:199-207; PMID:2647480; <http://dx.doi.org/10.1289/ehp.8980199>
104. Watari K, Tojo A, Nagamura-Inoue T, Matsuoka M, Irie S, Tani K, Yamada Y, Asano S. Hyperfunction of neutrophils in a patient with BCR/ABL negative chronic myeloid leukemia: a case report with in vitro studies. *Cancer* 2000; 89:551-60; PMID:10931454; [http://dx.doi.org/10.1002/1097-0142\(20000801\)89:3<551::AID-CNCR10>3.0.CO;2-E](http://dx.doi.org/10.1002/1097-0142(20000801)89:3<551::AID-CNCR10>3.0.CO;2-E)
105. Metcalf D. Implications of the polyfunctionality of hemopoietic regulators. *Stem Cells* 1994; 12(Suppl 1):259-75; PMID:7696965; <http://dx.doi.org/10.1002/stem.5530120722>
106. Baumann MA, Paul CC, Lemley-Gillespie S, Oyster M, Gomez-Cambronero J. Modulation of MEK activity during G-CSF signaling alters proliferative versus differentiative balancing. *Am J Hematol* 2001; 68:99-105; PMID:11559949; <http://dx.doi.org/10.1002/ajh.1160>
107. Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. *Am J Pathol* 2012; 181:1142-6; PMID:22841821; <http://dx.doi.org/10.1016/j.ajpath.2012.06.024>
108. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. *Cell Cycle* 2009; 8:1883-7; PMID:19448395; <http://dx.doi.org/10.4161/cc.8.12.8815>
109. Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). *Cell Cycle* 2010; 9:683-8; PMID:20139716; <http://dx.doi.org/10.4161/cc.9.4.10766>
110. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. *Aging (Albany NY)* 2012; 4:350-8; PMID:22683661
111. Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. *Cell Cycle* 2010; 9:4788-94; PMID:21150328; <http://dx.doi.org/10.4161/cc.9.24.14360>
112. Hentges KE, Sirry B, Gingeras AC, Sarbasov D, Sonenberg N, Sabatini D, Peterson AS. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. *Proc Natl Acad Sci U S A* 2001; 98:13796-801; PMID:11707573; <http://dx.doi.org/10.1073/pnas.241184198>
113. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. *Mol Cell Biol* 2004; 24:9508-16; PMID:15485918; <http://dx.doi.org/10.1128/MCB.24.21.9508-9516.2004>
114. Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Edenhofer F, Kiyama H, Yonezawa K, Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. *Mol Cell Biol* 2004; 24:6710-8; PMID:15254238; <http://dx.doi.org/10.1128/MCB.24.15.6710-6718.2004>
115. Shor B, Cavender D, Harris C. A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. *BMC Immunol* 2009; 10:28; PMID:19457267; <http://dx.doi.org/10.1186/1471-2172-10-28>
116. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. S6K1(-)/S6K2(-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol Cell Biol* 2004; 24:3112-24; PMID:15060135; <http://dx.doi.org/10.1128/MCB.24.8.3112-3124.2004>
117. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. *Genes Dev* 2000; 14:2712-24; PMID:11069888; <http://dx.doi.org/10.1101/gad.835000>
118. Santoro R, Blandino G. p53: The pivot between cell cycle arrest and senescence. *Cell Cycle* 2010; 9:4262-3; PMID:21057199; <http://dx.doi.org/10.4161/cc.9.21.13853>
119. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkouf A, Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. *Genome Biol* 2013; 14:R32; PMID:23594524; <http://dx.doi.org/10.1186/gb-2013-14-4-r32>
120. Serrano M. Shifting senescence into quiescence by turning up p53. *Cell Cycle* 2010; 9:4256-7; PMID:20980826; <http://dx.doi.org/10.4161/cc.9.21.13785>
121. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. *Cell Cycle* 2008; 7:842-7; PMID:18414039; <http://dx.doi.org/10.4161/cc.7.7.5657>
122. Roemer K. Are the conspicuous interdependences of fecundity, longevity and cognitive abilities in humans caused in part by p53? *Cell Cycle* 2010; 9:3438-41; PMID:20814241; <http://dx.doi.org/10.4161/cc.9.17.13001>
123. Bauer JH, Helfand SL. Sir2 and longevity: the p53 connection. *Cell Cycle* 2009; 8:1821; PMID:19471127; <http://dx.doi.org/10.4161/cc.8.12.9010>
124. Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods? *Cell Cycle* 2013; 12:20-5; PMID:23255104; <http://dx.doi.org/10.4161/cc.22912>
125. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borrás C, Flores JM, Viña J, Blasco MA, Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. *Nature* 2007; 448:375-9; PMID:17637672; <http://dx.doi.org/10.1038/nature05949>
126. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic Regulation by p53 Family Members. *Cell Metab* 2013; 18:617-33; PMID:23954639; <http://dx.doi.org/10.1016/j.cmet.2013.06.019>
127. Tower J. The genetic architecture of aging: sexual antagonistic pleiotropy of p53 and foxo. *Cell Cycle* 2010; 9:3840-1; PMID:20935483; <http://dx.doi.org/10.4161/cc.9.19.13464>
128. Kaeblerlein M, Kapahi P. The hypoxic response and aging. *Cell Cycle* 2009; 8:2324; PMID:19633411; <http://dx.doi.org/10.4161/cc.8.15.9126>
129. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. *Drug Discov Today* 2007; 12:218-24; PMID:17331886; <http://dx.doi.org/10.1016/j.drudis.2007.01.004>
130. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009; 460:392-5; PMID:19587680
131. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. Rapamycin, but not resveratrol or simvastatin, extends lifespan of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci* 2011; 66:191-201; PMID:20974732; <http://dx.doi.org/10.1093/geron/gdq178>
132. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 β and enhancing NMDA signaling. *Aging Cell* 2012; 11:326-35; PMID:22212527; <http://dx.doi.org/10.1111/j.1474-9726.2011.00791.x>
133. Zheng XF. Chemoprevention of age-related macular regeneration (AMD) with rapamycin. *Aging (Albany NY)* 2012; 4:375-6; PMID:22796653
134. Khanna A, Kapahi P. Rapamycin: killing two birds with one stone. *Aging (Albany NY)* 2011; 3:1043-4; PMID:22170738
135. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, Austad SN, Strong R, Richardson A, Hart MJ, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. *Neuroscience* 2012; 223:102-13; PMID:22750207; <http://dx.doi.org/10.1016/j.neuroscience.2012.06.054>
136. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. If started early in life, metformin treatment increases lifespan and postpones tumors in female SHR mice. *Aging (Albany NY)* 2011; 3:148-57; PMID:21386129
137. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, et al. Rapamycin slows aging in mice. *Aging Cell* 2012; 11:675-82; PMID:22587563; <http://dx.doi.org/10.1111/j.1474-9726.2012.00832.x>
138. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, et al. Rapamycin extends lifespan of Rb1^{+/-} mice by inhibiting neuroendocrine tumors. *Aging (Albany NY)* 2013; 5:100-10; PMID:23454836
139. Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. *Aging (Albany NY)* 2011; 3:1039-40; PMID:22147496
140. Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. *Aging (Albany NY)* 2011; 3:346-7; PMID:21483039
141. Huang X, Liu J, Withers BR, Samide AJ, Leggas M, Dickson RC. Reducing signs of aging and increasing lifespan by drug synergy. *Aging Cell* 2013; 12:652-60; PMID:23601176; <http://dx.doi.org/10.1111/acel.12090>
142. Santini E, Valjent E, Fisone G. mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter. *Cell Cycle* 2010; 9:2713-8; PMID:20581466; <http://dx.doi.org/10.4161/cc.9.14.12180>
143. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. *Aging Cell* 2013; 12:851-62; PMID:23734717; <http://dx.doi.org/10.1111/acel.12109>
144. Zhang XM, Li L, Xu JJ, Wang N, Liu WJ, Lin XH, Fu YC, Luo LL. Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression. *Gene* 2013; 523:82-7; PMID:23566837; <http://dx.doi.org/10.1016/j.gene.2013.03.039>

145. Glazer HP, Osipov RM, Clements RT, Sellke FW, Bianchi C. Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling. *Cell Cycle* 2009; 8:1738-46; PMID:19395857; <http://dx.doi.org/10.4161/cc.8.11.8619>
146. Ye L, Widlund AL, Sims CA, Lamming DW, Guan Y, Davis JG, Sabatini DM, Harrison DE, Vang O, Baur JA. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. *Aging (Albany NY)* 2013; 5:539-50; PMID:23929887
147. Hinojosa CA, Mgbemena V, Van Rookel S, Austad SN, Miller RA, Bose S, Orihuela CJ. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. *Exp Gerontol* 2012; 47:958-65; PMID:22981852; <http://dx.doi.org/10.1016/j.exger.2012.08.013>
148. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. *Sci Transl Med* 2011; 3:89ra58; PMID:21715679; <http://dx.doi.org/10.1126/scitranslmed.3002346>
149. Wang M, Miller RA. Fibroblasts from long-lived mutant mice exhibit increased autophagy and lower TOR activity after nutrient deprivation or oxidative stress. *Aging Cell* 2012; 11:668-74; PMID:22577861; <http://dx.doi.org/10.1111/j.1474-9726.2012.00833.x>
150. Kolosova NG, Muraleva NA, Zhdkankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV. Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. *Am J Pathol* 2012; 181:472-7; PMID:22683466; <http://dx.doi.org/10.1016/j.ajpath.2012.04.018>
151. Gems D, de la Guardia Y. Alternative Perspectives on Aging in *Caenorhabditis elegans*: Reactive Oxygen Species or Hyperfunction? *Antioxid Redox Signal* 2013; 19:321-9; PMID:22870907; <http://dx.doi.org/10.1089/ars.2012.4840>
152. Gems D, Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. *Annu Rev Physiol* 2013; 75:621-44; PMID:23190075; <http://dx.doi.org/10.1146/annurev-physiol-030212-183712>
153. Moskalev AA, Shaposhnikov MV. Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of *Drosophila melanogaster*. *Rejuvenation Res* 2010; 13:246-7; PMID:20017609; <http://dx.doi.org/10.1089/rej.2009.0903>
154. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of lifespan extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab* 2010; 11:35-46; PMID:20074526; <http://dx.doi.org/10.1016/j.cmet.2009.11.010>
155. Garelick MG, Mackay VL, Yanagida A, Academia EC, Schreiber KH, Ladiges WC, Kennedy BK. Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo. *Cell Cycle* 2013; 12:2493-504; PMID:23839034; <http://dx.doi.org/10.4161/cc.25512>
156. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, et al. Rapamycin Extends Life and Health in C57BL/6 Mice. *J Gerontol A Biol Sci Med Sci* 2013; PMID:23682161; <http://dx.doi.org/10.1093/gerona/glt056>
157. Fang Y, Bartke A. Prolonged rapamycin treatment led to beneficial metabolic switch. *Aging (Albany NY)* 2013; 5:328-9; PMID:23645164
158. Passtoors WM, Beekman M, Deelen J, van der Breggen R, Maier AB, Guigas B, Derhovanessian E, van Heemst D, de Craen AJ, Gunn DA, et al. Gene expression analysis of mTOR pathway: association with human longevity. *Aging Cell* 2013; 12:24-31; PMID:23061800; <http://dx.doi.org/10.1111/acel.12015>
159. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, Gutkind JS. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. *Cell Stem Cell* 2012; 11:401-14; PMID:22958932; <http://dx.doi.org/10.1016/j.stem.2012.06.007>
160. Iglesias-Bartolome R, Gutkind SJ. Exploiting the mTOR paradox for disease prevention. *Oncotarget* 2012; 3:1061-3; PMID:23165441
161. Zhou J, Freeman TA, Ahmad F, Shang X, Mangano E, Gao E, Farber J, Wang Y, Ma XL, Woodgett J, et al. GSK-3 α is a central regulator of age-related pathologies in mice. *J Clin Invest* 2013; 123:1821-32; PMID:23549082; <http://dx.doi.org/10.1172/JCI64398>
162. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53 $^{-/-}$ mice. *Aging (Albany NY)* 2012; 4:709-14; PMID:23123616
163. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53 $^{-/-}$ mice by delaying carcinogenesis. *Aging (Albany NY)* 2012; 4:715-22; PMID:23117593
164. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D. Hypothalamic programming of systemic ageing involving IKK- β , NF- κ B and GnRH. *Nature* 2013; 497:211-6; PMID:23636330; <http://dx.doi.org/10.1038/nature12143>
165. Tang Y, Cai D. Hypothalamic inflammation and GnRH in aging development. *Cell Cycle* 2013; 12:2711-2; PMID:23966154; <http://dx.doi.org/10.4161/cc.26054>
166. Perkey E, Fingar D, Miller RA, Garcia GG. Increased Mammalian target of rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and function. *J Immunol* 2013; 191:4648-55; PMID:24078700; <http://dx.doi.org/10.4049/jimmunol.1300750>
167. Wu X, Cao Y, Nie J, Liu H, Lu S, Hu X, Zhu J, Zhao X, Chen J, Chen X, et al. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. *Am J Pathol* 2013; 182:2005-14; PMID:23567640; <http://dx.doi.org/10.1016/j.ajpath.2013.02.012>
168. Zhang Y, Xu X, Ren J. mTOR overactivation and interrupted autophagy flux in obese hearts: a dicey assembly? *Autophagy* 2013; 9:939-41; PMID:23529215; <http://dx.doi.org/10.4161/auto.24398>
169. Rao RR, Li Q, Shrikant PA. Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation? *Cell Cycle* 2010; 9:2996-3001; PMID:20699660; <http://dx.doi.org/10.4161/cc.9.15.12359>
170. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. *Nature* 2009; 460:108-12; PMID:19543266; <http://dx.doi.org/10.1038/nature08155>
171. Nicoletti F, Lapenta C, Donati S, Spada M, Ranzani A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leukocytes-SCID reconstituted mice by rapamycin. *Clin Exp Immunol* 2009; 155:28-34; PMID:19076826; <http://dx.doi.org/10.1111/j.1365-2249.2008.03780.x>
172. Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, Kirk AD, Larsen CP, Ford ML. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. *J Immunol* 2010; 185:2004-8; PMID:20631309; <http://dx.doi.org/10.4049/jimmunol.1001176>
173. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. *Am J Transplant* 2011; 11:654-9; PMID:21446969; <http://dx.doi.org/10.1111/j.1600-6143.2011.03473.x>
174. Blagosklonny MV. How to save Medicare: the anti-aging remedy. *Aging (Albany NY)* 2012; 4:547-52; PMID:22915707
175. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. *Aging (Albany NY)* 2009; 1:281-8; PMID:20157517
176. Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, Ford ML, Ahmed R, Kirk AD, Larsen CP. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. *Am J Transplant* 2011; 11:613-8; PMID:21342450; <http://dx.doi.org/10.1111/j.1600-6143.2010.03473.x>
177. Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. *Transplantation* 2007; 84:1436-42; PMID:18091519; <http://dx.doi.org/10.1097/01.tp.0000290686.68910.bd>
178. Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkühl HB, Wang SS, Dong G, Witte S, Junge G, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. *Transpl Infect Dis* 2013; 15:150-62; PMID:23013440; <http://dx.doi.org/10.1111/tid.12007>
179. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. *Br J Cancer* 2011; 104:643-52; PMID:21285988; <http://dx.doi.org/10.1038/bjc.2011.15>